Current aspect of the diagnosis and management of migraine
https://doi.org/10.14412/2074-2711-2013-2421
Abstract
According to the WHO data from the Global Burden of Disease Study 2010, migraine is recognized to be third (14.4%) in its worldwide prevalence among men and women. In the Russian Federation, a population-based study has revealed migraine in 20.8% of cases. Questionnaires, disability scales, and headache diaries, the use of which helps a patient and a physician understand the nature, intensity, and frequency of headache attacks, to identify predisposing factors, and to assess treatment results, play a large role in the diagnosis of migraine. The stratified approach where which first-line therapy is determined depending on the intensity of migraine symptoms (the magnitude of headache and concomitant symptoms, including diminished working capacity) is applied to obtain better results in relieving migraine attacks. A migraine attack relieved with eletriptan 40 mg has proved to be highly effective in not only reducing the intensity of headache and concomitant symptoms within an hour after the intake of the drug, but also in promptly restoring the working capacity.
About the Author
Marina Igorevna KoreshkinaTsentr lecheniya golovnoy boli kliniki «Skandinaviya» OOO «AVA-PETER»
References
1. <div><p>Stovner L.J., Hagen K., Jensen R. et al. The global burden of headache: A documentation of headache prevalence and disability worldwide. Cephalalgia 2007;27:193-210.</p><p>World heath Organization. World health report 2001. Geneva: WHO 2001.</p><p>World Health Organization and Lifting The Burden. Atlas of headache disorders and resources in the world 2011. Geneva: WHO.</p><p>Табеева Г.Р., Яхно Н.Н. Мигрень. М.: ГЭОТАР-Медиа, 2011;620 с.</p><p>Salomon J.A., Vos T., Hogan D.R. et al. Common values in assessing health outcomes from disease and injury: disability weights measurement study for the Global Burden of Disease Study 2010. Lancet 2012;380:2129-44.</p><p>Vos T., Flaxman A.D., Naghavi M. et al. Years lived with disability (YLD) for 1160 sequelae of 289 diseases and injuries 1990—2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012;380:2163-96.</p><p>Ayzenberg I., Katsarava Z., Sborowski A. et al. The prevalence of primary headache disorders in Russia: A countrywide survey. Cephalalgia 2012;32:373.</p><p>Jensen R., Stovner L. Epidemiology and comorbidity of headache. Lancet Neurology 2008;7(4):354-62.</p><p>Stovner L.J., Hagen K., Jensen R. et al. The global burden of headache: a documentation of headache prevalence and disability worldwide. Cephalalgia 2007;27:193-210.</p><p>Steiner T.J., Stewart W.F. The prevalence and disability of adult in England and their relathionships to age, gender and ethnicity. Cephahlalgia 2003;23:519-27.</p><p>Bloudek L.M., Stokes M., Buse D.C. et al. Cost of healthcare for patients with migraine in five European countries: results from the International Burden of Migraine Study (IBMS). J Headache Pain 2012;13:361-78.</p><p>Diener H.-C., Gaul C., Jensen R. et al. Integrated headache care. Cephalalgia 2011;31(9):1039—47.</p><p>Осипова В.В., Азимова Ю.Э., Табеева Г.Р. и др. Диагностика головных болей в России и странах постсоветского пространства: состояние проблемы и пути ее решения. Анн клин и эксперим неврол 2012;6(2):16—21.</p><p>Амелин А.В., Богданова Ю.Н., Корешкина М.И. и др. Диагностика первичных и симптоматических форм хронической ежедневной головной боли. Журн неврол и психиатр 2011;111:4:69—71.</p><p>Walling A.D., Wolley D.C., Molgaard C., Kallail K.J. Patients' satisfactions with migraine management in family physicians. J Am Board Fam Prack 2005;18:563-6.</p><p>Стайнер Т. Дж., Пемелера К., Йенсен Р. и др. Европейские принципы ведения паци ентов с наиболее распространенными формами головной боли в общей практике. Практическое руководство для врачей. Под ред. В.В. Осиповой, Т.Г. Вознесенской, Г.Р. Табеевой. М.: ООО ОГГИ. Рекламная продукция, 2010;56 с.</p><p>Lipton R.B., Bigal M.E., Rush S.R. et al. Migraine practice among neurologists. Neurology 2004;62:1926-31.</p><p>Jensen R., Bendtsen L. Principles and tools: questionnaires, structured interviews, diaries and calendars. In: Classification and diagnosis of headache disorders. J. Olesen (ed.) Oxford: Oxford University Press, 2005;20-7.</p><p>Russell M.B., Rasmussen B.K., Brennum J. et al. Presentation of a new instrument: the diagnostic headache diary. Cephalalgia 1992:12:369-74.</p><p>Nappi G., Jensen R., Nappi R.E. et al. Diaries and calendars for migraine. A review. Cephalalgia 2006;26:905-16.</p><p>Cousins G., Hijazze S, van de Laar F.A., Fahey T. Diagnostic Accuracy of the ID Migraine: A Systematic Review and MetaAnalysis. Headache: J Head and Face Pain 2011:51(7):1140-8.</p><p>Jensen R., Tassorelli C., Rossi P. and the Basic Diagnostic Headache Diary Study Group. A basic diagnostic headache diary (BDHD) is well accepted and useful in the diagnosis of headache. Cephalalgia 2011:31(15):1549—60.</p><p>Корешкина М.И. Использование дневника головной боли в диагностике и лечении мигрени. Фарматека 2011;19(232):55—60.</p><p>Stewart W.F., Lipton R.B., Dowson A.J., Sawyer J. Development and testing of the migraine disability assessment (MIDAS) questionnaire to assess headache-related disability. Neurology 2001;56:20—8.</p><p>Becker W.J. Weather and migraine: Can so many patients be wrong? Cephalalgia 2011;31(4):387—90.</p><p>Zebenholzer K., Rudel E., Frantal S. et al. Migraine and weather: A prospective diary-based analysis. Cephalalgia 2011;31(4):391—400.</p><p>Hauge A.W., Kirchmann M., Olesen J. Characterization of consistent triggers of migraine with aura. Cephalalgia 2011;31(4):416—38.</p><p>Данилов А.Б. Роль пола и гендера при мигрени и головной боли напряжения (клинико-психофизиологическое исследование). Дис.. докт. мед. наук. М., 2007.</p><p>Peterlin B.L., Gupta S., Ward T., MacGregor A. Sex Matters: Evaluating Sex and Gender in migraine and Headache Reseach. Headache 2011;51:839—42.</p><p>Hu X.H., Markson L.E., Lipton R.B. et al. Buren of migraine in the Unated States: Disability and economic costs. Arch Int Med 1999;159:813—8.</p><p>MacGregor E.A., Rosenberg J.D., Kurth T. Sex-Related Differences in Epidemiological and Clinic-based Headache Studies. Headache 2011;51:843—59.</p><p>Odegard S.S., Engstrom M., Sand T. et al. Associations between sleep disturbance and primary headaches: the third Nord-Trondelag Health Study. J Headache Pain 2010;11:197—206.</p><p>Silberstein S.D. Migraine. Lancet 2004;363:381—91.</p><p>Амелин А.В., Игнатов Ю.Д., Скоромец А.А., Соколов А.Ю. Мигрень. Патогенез, клиника, фармакотерапия: руководство для врачей. М.: МЕДпресс-информ, 2011;265 с.</p><p>Ferrari M.D., Goadsby P.J., Roon K.I. et al. Triptans (serotonin, 5-HT1B/1D agonists) in migraine: detailed results and methods of a meta-analysis of 53 trials. Cephalalgia 2002;22:633—58.</p><p>Santanello N.C., Davies G., Allen C. et al. Determinants of migraine-specific quality of life. Cephalalgia 2002;22:680—5.</p><p>Jelinssski S.E., Becker W.J., Christie S.N. et al. Clinical feature and pharmacological treatment of migraine patients referred to headache specialists in Canada. Cephalalgia 2006;26:578—88.</p><p>Ifergane G., Wirguin I., Shvartzmann P. Triptan- why once? Headache 2006; 46:1261—3.</p><p>Lipton R.B., Stewart W.F., Stone A.M. et al. Stratified care vs step care strategies for migraine: the Disability in Strategies of Care (DISC) Study: A randomized trial. JAMA 2000;284:2599—605.</p><p>Diamond M.I., Cady R. Initiating and optimizing acute therapy for migraine: the role of patient-centered stratified care. Am J Med 2005;118(Suppl 1): S18—S27.</p><p>Hoskin K.L., Kaube H., Goadsby P.J. Sumatriptan can inhibit trigeminal afferents by an exclusively neural mechanism. Brain 1996;119(5):1419—28.</p><p>Shields K.G., Goadsby P.J. Serotonin receptors modulate trigeminovascular responses in ventroposteromedial nucleus of thalamus: a migraine target? Neurobiol Dis 2006;23:491—501.</p><p>Tfelt-Hansen P., Olesen J. Increasing the effect of triptan in migraine. Lancet 2006;368:1313—4.</p><p>Bigal M.E., Lipton R.B., Krrymchantowalski A.V. The medical management of migraine, Ann J Ther 2004;11:130—40.</p><p>Lante’ri-Minet M., Mick G., Allaf B. Early dosing and efficacy of triptans in acute migraine treatment: the TEMPO study. Cephalalgia 2012;32(3):226—35.</p><p>Dowson A., Massiou H., Lainez J., Cabarrocas X. Almotriptan improves response rates when treatment is within 1 hour of migraine onset. Headache 2004;44:318—22.</p><p>Cady R., Martin V., Mauskop A. et al. Efficacy of rizatriptan 10 mg administered early in a migraine attack. Headache 2006;46:914—24.</p><p>Goadsby P.J., Zanchin G., Geraud G. et al. Early versus non-early intervention in acute migraine — «Act when Mild — AwM». A dou ble-blind placebo-controlled trial of almotriptan. Cephalalgia 2008;28:383—91.</p><p>Burstein R., Collins B., Jakubowski M. Defeating migraine pain with triptans: a race against the development of cutaneous allodynia. Ann Neurol 2004;55:19—26.</p><p>Wu J., Hughes M.D., Hudson M.F., Wagner P.J. Antimigraine medication use and associated health care costs in employed patients. J Headache Pain 2012; 13:121—27.</p><p>Rapoport A.M., Terre S.J., Sheftell F.D. et al. Which triptan for which patient? Neurol Sci 2006;27:S123—S129.</p><p>Ferrari M.D. Current perspectives of effective migraine treatment: are small clinical difference important for patients? Drug of Today 2003; 9(Suppl D):37—41.</p><p>Diener H.C., Gendolla A., Gebert I., Beneke M. Almotriptan in migraine patients who respond poorly to oral sumatriptan: a double-blind, randomized trial. Headache 2005;45:874—82.</p><p>Mathew N.T., Hettiaraccchchi J., Adelman J. Tolerability and safety of eletriptan in the treatment of migraine: a comprehensive review. Headache 2003;43:962—74.</p><p>Takiya I., Piccininni L.C., Kamath V. Safety and efficacy of eletriptan in the treatment of acute migraine. Pharmacotherapy 2006;26:115—28.</p><p>Chia Y.-C., Lim S.-H., Wang S.-J. et al. Efficacy of eletriptan in migraineurs with persistent poor response to nonsteroid anti-inflam-atory drugs. Headache 2003;43:209—16.</p><p>Martin V.T., Valade D., Almas M., Hettiarachchi J. Efficacy of eletriptan in trip-tan-native patients: result of combined analysis. Headache 2007;47:1811—18.</p><p>Diener H.-C., Ryan R., Sun W., Hetliarachchi J. The 40 mg dose of eletriptan comparative efficacy and tolerability versus sumatriptan 100mg. Eur J Neurol 2004;11:125—34.</p><p>Ho A.P., Dahlof C.G.H., Silberstein S.D. et al. Randomized, controlled, trial of telcagepant over four migraine attacks. Cephalalgia 2010;30(12):1443—57.</p><p>Diener H.-C., Barbanti P., Dahlof C. et al. 44370 TA, an oral CGRP antagonist for the treatment of acute migraine attacks: Results from a phase II study. Cephalalgia 2011;31(5):573—84.</p></div><br />
Review
For citations:
Koreshkina MI. Current aspect of the diagnosis and management of migraine. Nevrologiya, neiropsikhiatriya, psikhosomatika = Neurology, Neuropsychiatry, Psychosomatics. 2013;5(2):92-96. (In Russ.) https://doi.org/10.14412/2074-2711-2013-2421
Views:
1094
Email this article 